AU2011262308B2 - Methods and compositions for oral pharmaceutical therapy - Google Patents

Methods and compositions for oral pharmaceutical therapy Download PDF

Info

Publication number
AU2011262308B2
AU2011262308B2 AU2011262308A AU2011262308A AU2011262308B2 AU 2011262308 B2 AU2011262308 B2 AU 2011262308B2 AU 2011262308 A AU2011262308 A AU 2011262308A AU 2011262308 A AU2011262308 A AU 2011262308A AU 2011262308 B2 AU2011262308 B2 AU 2011262308B2
Authority
AU
Australia
Prior art keywords
cancer
agent
composition
subject
taurolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011262308A
Other languages
English (en)
Other versions
AU2011262308A1 (en
Inventor
Peter Geistlich
Rolf W. Pfirrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geistlich Pharma AG
Original Assignee
Geistlich Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geistlich Pharma AG filed Critical Geistlich Pharma AG
Publication of AU2011262308A1 publication Critical patent/AU2011262308A1/en
Application granted granted Critical
Publication of AU2011262308B2 publication Critical patent/AU2011262308B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2011262308A 2010-06-01 2011-06-01 Methods and compositions for oral pharmaceutical therapy Active AU2011262308B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35018310P 2010-06-01 2010-06-01
US61/350,183 2010-06-01
US37031510P 2010-08-03 2010-08-03
US61/370,315 2010-08-03
PCT/IB2011/001539 WO2011151722A2 (en) 2010-06-01 2011-06-01 Methods and compositions for oral pharmaceutical therapy

Publications (2)

Publication Number Publication Date
AU2011262308A1 AU2011262308A1 (en) 2013-01-10
AU2011262308B2 true AU2011262308B2 (en) 2014-07-31

Family

ID=45067142

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011262308A Active AU2011262308B2 (en) 2010-06-01 2011-06-01 Methods and compositions for oral pharmaceutical therapy

Country Status (9)

Country Link
US (1) US9028866B2 (enExample)
EP (1) EP2575783B1 (enExample)
JP (2) JP5926243B2 (enExample)
CN (1) CN103118669B (enExample)
AU (1) AU2011262308B2 (enExample)
BR (1) BR112012030641B8 (enExample)
CA (1) CA2801309C (enExample)
ES (1) ES2614878T3 (enExample)
WO (1) WO2011151722A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301374B2 (en) * 2012-05-15 2016-03-29 Koninklijke Philips N.V. Control of lighting devices
US20190381060A1 (en) 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
CA3010981C (en) * 2016-01-11 2024-09-17 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
US20190381058A1 (en) * 2016-01-11 2019-12-19 Cormedix Inc. Methods and compositions for treating neuroblastoma in a juvenile mammalian body
US11541061B2 (en) 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
PL3709979T3 (pl) 2017-11-17 2025-03-24 Evonik Operations Gmbh Sposób wytwarzania powlekanej kapsułki twardej
CN113347976A (zh) * 2018-08-28 2021-09-03 科医公司 用牛磺罗定水解产物进行的神经母细胞瘤治疗
WO2020047530A1 (en) * 2018-08-31 2020-03-05 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
WO2020234833A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Method for treating, preventing, inhibiting or reducing cytokine release
US20220323452A1 (en) * 2019-05-22 2022-10-13 Geistlich Pharma Ag Methods and compositions for inhibiting gapdh
CN111671758A (zh) * 2020-07-06 2020-09-18 长春迈灵生物工程有限公司 牛磺罗定在制备抗hiv病毒药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999034805A1 (en) * 1998-01-08 1999-07-15 Ed Geistlich Söhne Ag Für Chemische Industrie Use of antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection
WO2001039763A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
US6251896B1 (en) * 1999-03-24 2001-06-26 Carter-Wallace, Inc. Compositions and methods for the management of Crohn's disease
EP1116488A2 (en) * 2000-01-05 2001-07-18 Ed. Geistlich Söhne Ag Für Chemische Industrie Treatment of inflammatory Bowel disease
US20050053660A1 (en) * 2001-01-31 2005-03-10 Roehm Gmbh & Co. Kg Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
US20060198886A1 (en) * 2005-03-01 2006-09-07 Jenkins Richard B Medicament having coated methenamine combined with acidifier

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US6555534B1 (en) * 1998-09-11 2003-04-29 Medpointe Healthcare Inc. Method and compositions for the control or eradication of Helicobacter pylori
WO2001013957A2 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
AU779362B2 (en) * 2000-10-27 2005-01-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
EP2260845A3 (fr) 2002-06-21 2012-08-22 L'Oréal Utilisation de polyphénol pour le traitement de l'alopécie
EA015781B1 (ru) * 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
ATE414518T1 (de) * 2006-07-25 2008-12-15 Claus Herdeis Herstellung von antimikrobiellen formulierungen unter verwendung von 7-oxa-2-thia 1,5- diazabicycloä3.3.1ünonan-2,2-dion

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999034805A1 (en) * 1998-01-08 1999-07-15 Ed Geistlich Söhne Ag Für Chemische Industrie Use of antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection
US6251896B1 (en) * 1999-03-24 2001-06-26 Carter-Wallace, Inc. Compositions and methods for the management of Crohn's disease
WO2001039763A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
EP1116488A2 (en) * 2000-01-05 2001-07-18 Ed. Geistlich Söhne Ag Für Chemische Industrie Treatment of inflammatory Bowel disease
US20050053660A1 (en) * 2001-01-31 2005-03-10 Roehm Gmbh & Co. Kg Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
US20060198886A1 (en) * 2005-03-01 2006-09-07 Jenkins Richard B Medicament having coated methenamine combined with acidifier

Also Published As

Publication number Publication date
CA2801309C (en) 2018-07-17
US20130089606A1 (en) 2013-04-11
BR112012030641B8 (pt) 2022-06-14
CA2801309A1 (en) 2011-12-08
AU2011262308A1 (en) 2013-01-10
JP2013527224A (ja) 2013-06-27
HK1183228A1 (zh) 2013-12-20
WO2011151722A2 (en) 2011-12-08
US9028866B2 (en) 2015-05-12
CN103118669B (zh) 2016-01-13
JP2016155826A (ja) 2016-09-01
JP5926243B2 (ja) 2016-05-25
BR112012030641B1 (pt) 2022-05-24
BR112012030641A2 (pt) 2016-08-16
ES2614878T3 (es) 2017-06-02
WO2011151722A3 (en) 2012-05-24
EP2575783B1 (en) 2017-01-11
EP2575783A2 (en) 2013-04-10
CN103118669A (zh) 2013-05-22

Similar Documents

Publication Publication Date Title
CA2801309C (en) Methods and compositions for oral pharmaceutical therapy
JP6092514B2 (ja) ５−フルオロシトシン製剤およびその使用
JP4549445B2 (ja) シスプラチン含有マイクロ顆粒
CN101360495B (zh) 对癌症病人给药mTOR抑制剂
CN110087632B (zh) 乳酸钙组合物和使用方法
JP2006515885A (ja) 癌の処置のための併用療法
PL200957B1 (pl) Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej
SK9022002A3 (en) Sustained-release formulation of a cyclooxygenase-2 inhibitor
US20200397726A1 (en) Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms
MD3684344T2 (ro) Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
WO2001078681A1 (en) Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof
JP2002504108A (ja) 一種のａｃｅ阻害剤を備えた調節放出性薬剤学的製剤
US20230137776A1 (en) Use of colchicine to inhibit tumor growth and metastases
WO2008066783A2 (en) Therapeutic materials and methods
CN104869985A (zh) 硝酸氨基烷基酯的延长释放组合物
CN107334767A (zh) 一种哒嗪酮类化合物在肿瘤治疗中的应用
WO2018129061A1 (en) Antimicrobial delivery system for the prevention and treatment of infections in the colon
JP4707668B2 (ja) オキソプラチン、その塩および誘導体を含む医薬組成物
RU2195937C1 (ru) Комбинированный противотуберкулезный препарат (ризобутол)
JP6887043B2 (ja) コルヒチンの徐放性製剤およびその使用方法
HK1183228B (en) Methods and compositions for oral pharmaceutical therapy
CZ205596A3 (en) Galenic form of 5-nitroimidazole derivatives and pharmaceutical composition containing thereof
HK40103513A (en) Pharmaceutical composition comprising calcium lactate and usage thereof
HK1173387A (en) Use of a rapamycin derivative for the treatment of cancer
JPH0357881B2 (enExample)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)